Purchase Order HHSN302201600166P

<p>The National Human Genome Research Institute awarded a purchase order to Omega Bio-Tek, Inc. for $14,948.00 on September 13, 2017. Work is performed in Bethesda, Maryland. The order procures supplies for research under firm fixed pricing, with an ultimate completion date of October 12, 2017. No small business set-aside applied.</p>

<p>The National Human Genome Research Institute awarded a purchase order to Eurofins Genomics LLC for $14,975.00 on December 13, 2016, with a firm fixed price for research studies. Place of performance is Bethesda, Maryland. The order was not set-aside and carries an ultimate completion date of January 11, 2021.</p>

<p>The National Human Genome Research Institute awarded a purchase order to Life Technologies Corporation valued at $4,452.00 on September 15, 2017, for firm fixed price commercial items. Place of performance is Bethesda, Maryland. The order has an ultimate completion date of December 31, 2017. No set-aside was used.</p>

<p>The National Human Genome Research Institute issued a purchase order to Qiagen, LLC on August 17, 2016, for $4,285.40 under a firm fixed-price arrangement. Performance is located in Bethesda, Maryland, with an ultimate completion date of December 23, 2020. No set-aside was applied to this order. The source does not specify the particular products or services procured under this purchase order.</p>

The National Human Genome Research Institute awarded a purchase order to Thermo Electron North America LLC on July 11, 2016, for $23,246.64 with a firm fixed price structure and an ultimate completion date of December 23, 2020. Place of performance is Bethesda, Maryland. The order procures scientific instrumentation and laboratory equipment maintenance services from a for-profit vendor specializing in advanced analytical technologies including mass spectrometers, chromatography systems, and...

<p>The National Human Genome Research Institute awarded a purchase order to Life Technologies Corporation for $4,427.49 on December 1, 2017, with ultimate completion by December 31, 2018. No set-aside was applied. Place of performance is Bethesda, Maryland. The order procures scientific supplies or equipment typical of Life Technologies' federal portfolio, which includes laboratory instrumentation, reagents, and consumables for genomic research applications.</p>

<p>The National Human Genome Research Institute awarded a purchase order to Fisher Scientific Company L.L.C. for $107,000 on August 7, 2018. The order procures a Cytation 5 imaging multi-mode system and BioSpa automated incubator for placement of performance in Bethesda, Maryland. The purchase order is a firm fixed price acquisition with an ultimate completion date of September 6, 2018.</p>

<p>The National Human Genome Research Institute awarded a purchase order to Rees Scientific Corporation valued at $4,241.54 on August 9, 2016. Work is performed in Bethesda, Maryland. The order is firm fixed price with no small business set-aside. Ultimate completion is scheduled for December 23, 2020. The source does not specify the goods or services procured.</p>

The National Human Genome Research Institute awarded a purchase order to Government Scientific Source Inc., a small business, for $124,200 on July 8, 2026. The order procures an Opentrons Flex V2 robot, a laboratory automation system that improves genome coverage uniformity, enables accurate variant calling compared to emulsion PCR chemistry, and reduces hands-on time to ten minutes. Place of performance is Bethesda, Maryland. The purchase order carries firm fixed-price pricing with no set-aside...

The National Human Genome Research Institute issued a $12,028 delivery order to Beckman Coulter, Inc. on December 18, 2018, under a single-award Indefinite Delivery Contract with the Office of Logistics and Acquisition Operations for biomedical laboratory equipment, reagents, software, maintenance, and related services. Place of performance is Bethesda, MD. The order carried an ultimate completion date of September 30, 2019. Pricing was firm fixed price with no set-aside designation.